Company Profile

Colby Pharmaceutical Company
Profile last edited on: 5/23/2019      CAGE: 47VE9      UEI: E485BYCZNN71

Business Identifier: Signal transduction modulators and immune modulators for various diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5941 Optical Court Suite 223
San Jose, CA 95138
   (650) 333-3150
Location: Multiple
Congr. District: 19
County: Santa Clara

Public Profile

Colby Pharmaceutical Company, a clinical stage drug development company organized around non-toxic signal transduction and hypoxia inhibitor drug therapeutics specifically targeting survival pathways in solid tumor cells, immune or immune suppressed cells, and vas-occlusive conditions. The firm has developed a proprietary system for direct Intra Lymph Node Injection (ILNI™). This ILNI™ Platform Technology has been developed for allergy desensitization, cancer immunotherapy and infectious disease vaccination. In collaboration with others, Colby is working on developing anti-inflammatory, -cancer and -autoimmune disease therapeutics. With clinical research professionals, the firmis achieving human safety and efficacy in solid or hematological malignancies treated with proprietary cancer-specific targeted agents, using novel intralymphnode and other advanced delivery technologies resulting in significant long-term durable cancer patient remissions and potential cures. The firm's anti-inflammatory medicines are molecularly-targeted small molecule-, bio- and immuno-therapeutics advancing cost-effective clinical practices and favorable patient outcomes. Colby's molecularly targeted agents treat chronic inflammatory or hyper-proliferative diseases and are expanding clinical applications beyond cancer into targeted allergy, pain, regenerative and auto-immune medicines.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Anne Vallerga -- Co-Founder and President

  David Zarling -- President

  Hirak S Basu -- Chief Scientific Officer

  Jeffery Fairman

  Minesh Mehta

  Kenneth Narducy -- COO